Navigation Links
Brazil's National Health System Currently Provides Coverage for 22 Drugs that are Distributed Free of Charge to Over 300,000 HIV-Infected Patients

BURLINGTON, Mass., Dec. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Brazil's National Health System (SUS) currently provides coverage for 22 drugs that are distributed free of charge to more than 300,000 HIV-infected patients. Covered drugs are provided free of charge to eligible patients under the Strategic Program for Pharmaceutical Assistance (CESAF), managed at state and municipal levels. Drugs not covered by the SUS, such as the fixed-dose combinations (FDCs) Gilead's Truvada, GlaxoSmithKline's Kivexa and GlaxoSmithKline's Triovir, must be paid for out-of-pocket or accessed via judicial action. Surveyed physicians indicate that less than 10 percent of patients receiving a nucleotide reverse transcriptase inhibitor (NRTI) receive treatment with FDC-NRTI.


The special report entitled HIV in Brazil: Physician & Payer Perspectives on the Market Access Hurdles and Levers that Impact this Dynamic Market finds that access to antiretroviral (ARV) therapies is strictly defined by government-issued guidelines, known as the Clinical Protocol and Therapeutic Guidelines (PCDTs). The Ministry of Health, through the PCDTs, restricts the use of new, premium-priced therapies to third-line therapy, following proven failure of less costly therapies. Moreover, while providing access to several ARV brands, the Brazilian government has historically threatened imposing compulsory licensing to contain the costs associated with the purchase of HIV drugs, which it considers to be of public interest. Moreover, in the past six years the government has excluded certain HIV therapies from patent protection (Gilead/United Medical's Viread and AbbVie's Kaletra), and has granted a compulsory license for Merck's Stocrin.

"The Brazilian government has established Productive Development Partnerships (PDPs) with domestic and foreign manufacturers to locally produce and supply the SUS with a single-tablet regimen (STR), an FDC and important new third-line ARVs such as Merck's Isentress," said Decision Resources Analyst Denise Ferreira, Ph.D. "Payers believe that from the moment the ARVs from these PDPs become available, the recommendation from the PCDT may change to accommodate use of these drugs in early lines of therapy."

The report also finds that the STR market is unexploited in Brazil, and that Gilead's Atripla and Gilead's Eviplera STRs are not yet approved in this market. Payers indicate that STRs combining novel agents, or agents currently not covered by the SUS may see future reimbursement, pending demonstration of cost-effectiveness compared with currently funded ARVs.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 2013 Report on the International Cardiac Monitoring & Cardiac Rhythm Management (CRM) Market - Includes Forecasts to 2017
2. 2013 Report on the International Anesthesia And Respiratory Devices Market - Includes Forecastto 2019
3. 2013 Report on the International Pain Management Therapeutics Market - Includes Forecast to 2018
4. ULURU Inc. Announces the Expansion of the International Marketing Network
5. Neuraltus Pharmaceuticals NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND
6. Fairfield County Resident Named Foundation Fighting Blindness National Trustee
7. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
8. Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals
9. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
10. National Decision Support Company offers free access to ACR Select
11. Concord Medical Signs MOU with Shanghai New Hongqiao International Medical Center and GE Healthcare to Establish a Medical Imaging Diagnosis Center
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to offer their patients the many benefits of the revolutionary BIOLASE WaterLase iPlus ... cutting and scraping tools traditionally used by a dentist in Gettysburg, PA ...
(Date:11/24/2015)... ... 24, 2015 , ... ThirdLove, the fast-growing bra company that ... offering 40% off select bras and underwear styles, now through Saturday, November 28th. ... technology and the latest fashion, quickly becoming the next generation of luxury bras. ...
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), ... & Company as its newest Partner Firm. Based in Jefferson City, Missouri, their ... trusted advisor regardless of whether that client is a business, a family, or ...
Breaking Medicine News(10 mins):